Alzheimers Research & Therapy

Article	Citations
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody	350
Immediate and long-term consequences of COVID-19 infections for the development of neurological disease	324
Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval	204
The clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease	171
Aducanumab produced a clinically meaningful benefit in association with amyloid lowering	141
Cognitive impact of COVID-19: looking beyond the short term	139
Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer’s disease and PET amyloid-positive patient identification	132
Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology	117
Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment	109
Randomized crossover trial of a modified ketogenic diet in Alzheimer’s disease	106
Network medicine links SARS-CoV-2/COVID-19 infection to brain microvascular injury and neuroinflammation in dementia-like cognitive impairment	95
A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer’s dementia	93
Imaging biomarkers in neurodegeneration: current and future practices	86
APOE4 is associated with cognitive and pathological heterogeneity in patients with Alzheimer’s disease: a systematic review	84
Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231	82
Mesenchymal stem cell-derived exosome: a promising alternative in the therapy of Alzheimer’s disease	79
Machine learning methods for predicting progression from mild cognitive impairment to Alzheimer’s disease dementia: a systematic review	73
Empagliflozin reduces vascular damage and cognitive impairment in a mixed murine model of Alzheimer’s disease and type 2 diabetes	72
Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer’s disease	70
Lecanemab in patients with early Alzheimer’s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study	68
Reproducibility of EEG functional connectivity in Alzheimer’s disease	68
Microglia prevent beta-amyloid plaque formation in the early stage of an Alzheimer’s disease mouse model with suppression of glymphatic clearance	65
The combined effects of microglia activation and brain glucose hypometabolism in early-onset Alzheimer’s disease	62
The association of APOE ε4 with cognitive function over the adult life course and incidence of dementia: 20 years follow-up of the Whitehall II study	59
Metabolic phenotyping reveals a reduction in the bioavailability of serotonin and kynurenine pathway metabolites in both the urine and serum of individuals living with Alzheimer’s disease	58

Effect of APOE ε4 genotype on amyloid-β and tau accumulation in Alzheimer’s disease	58
Estimating prevalence of subjective cognitive decline in and across international cohort studies of aging: a COSMIC study	57
White matter hyperintensities across the adult lifespan: relation to age, Aβ load, and cognition	57
Comparison of ELISA- and SIMOA-based quantification of plasma Aβ ratios for early detection of cerebral amyloidosis	55
Tau-PET and in vivo Braak-staging as prognostic markers of future cognitive decline in cognitively normal to demented individuals	54
Loss of perivascular aquaporin-4 localization impairs glymphatic exchange and promotes amyloid β plaque formation in mice	54
Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer’s disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two	54
Intracerebroventricular injection of human umbilical cord blood mesenchymal stem cells in patients with Alzheimer’s disease dementia: a phase I clinical trial	53
Metformin attenuates plaque-associated tau pathology and reduces amyloid-β burden in APP/PS1 mice	52
A phase II randomized trial of sodium oligomannate in Alzheimer’s dementia	52
The dynamics of biomarkers across the clinical spectrum of Alzheimer’s disease	51
Effects of low- and high-intensity physical exercise on physical and cognitive function in older persons with dementia: a randomized controlled trial	51
Portals to frailty? Data-driven analyses detect early frailty profiles	50
Validation of amyloid PET positivity thresholds in centiloids: a multisite PET study approach	49
The Alzheimer’s disease drug development landscape	48
One third of dementia cases can be prevented within the next 25 years by tackling risk factors. The case “for” and “against”	47
A selective p38α/β MAPK inhibitor alleviates neuropathology and cognitive impairment, and modulates microglia function in 5XFAD mouse	47
Enhanced diagnostic accuracy for neurocognitive disorders: a revised cut-off approach for the Montreal Cognitive Assessment	47
Identification of potential blood biomarkers for early diagnosis of Alzheimer’s disease through RNA sequencing analysis	47
An integrative multi-omics approach reveals new central nervous system pathway alterations in Alzheimer’s disease	47
Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer’s disease pathology and clinical disease progression	47
Retinal microvasculature dysfunction is associated with Alzheimer’s disease and mild cognitive impairment	46
Repurposed agents in the Alzheimer’s disease drug development pipeline	45
Subjective cognitive decline, anxiety symptoms, and the risk of mild cognitive impairment and dementia	45
A comparative study of the effects of Aducanumab and scanning ultrasound on amyloid plaques and behavior in the APP23 mouse model of Alzheimer disease	45
In vivo tau pathology is associated with synaptic loss and altered synaptic function	45
Association of Aβ deposition and regional synaptic density in early Alzheimer’s disease: a PET imaging study with [11C]UCB-J	45
The accuracy and robustness of plasma biomarker models for amyloid PET positivity	44
Multi-platform proteomic analysis of Alzheimer’s disease cerebrospinal fluid and plasma reveals network biomarkers associated with proteostasis and the matrisome	43
Improving the resistance and resilience framework for aging and dementia studies	41
Neuropsychiatric symptoms in cognitively normal older persons, and the association with Alzheimer’s and non-Alzheimer’s dementia	41
Quantitative EEG as a biomarker in mild cognitive impairment with Lewy bodies	40
Data-driven FDG-PET subtypes of Alzheimer’s disease-related neurodegeneration	40
Alzheimer’s disease progression characterized by alterations in the molecular profiles and biogenesis of brain extracellular vesicles	40
Optical coherence tomography angiography as a potential screening tool for cerebral small vessel diseases	40
Functional neuroimaging in subjective cognitive decline: current status and a research path forward	40
AlzGPS: a genome-wide positioning systems platform to catalyze multi-omics for Alzheimer’s drug discovery	40
Hormone replacement therapy is associated with improved cognition and larger brain volumes in at-risk APOE4 women: results from the European Prevention of Alzheimer’s Disease (EPAD) cohort	39
Sex differences in neuropsychiatric symptoms in Alzheimer’s disease dementia: a meta-analysis	39
Relevance of biomarkers across different neurodegenerative diseases	39
EEG alpha reactivity and cholinergic system integrity in Lewy body dementia and Alzheimer’s disease	39
The cholinergic system in subtypes of Alzheimer’s disease: an in vivo longitudinal MRI study	39
Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging	38
GPS driving: a digital biomarker for preclinical Alzheimer disease	38
Mild behavioral impairment: measurement and clinical correlates of a novel marker of preclinical Alzheimer’s disease	38
Plasma biomarker profiles and the correlation with cognitive function across the clinical spectrum of Alzheimer’s disease	36
Associations of Alzheimer’s disease risk variants with gene expression, amyloidosis, tauopathy, and neurodegeneration	36
Human neural stem cell-derived extracellular vesicles mitigate hallmarks of Alzheimer’s disease	36
Melatonin levels in the Alzheimer’s disease continuum: a systematic review	36
A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer’s disease	35

The insulin resistance by triglyceride glucose index and risk for dementia: population-based study	35
Artificial intelligence framework identifies candidate targets for drug repurposing in Alzheimer’s disease	34
Modifiable risk factors for dementia and dementia risk profiling. A user manual for Brain Health Services—part 2 of 6	34
Health-related quality of life in people with predementia Alzheimer’s disease, mild cognitive impairment or dementia measured with preference-based instruments: a systematic literature review	34
Are ketogenic diets promising for Alzheimer’s disease? A translational review	34
Multidomain interventions: state-of-the-art and future directions for protocols to implement precision dementia risk reduction. A user manual for Brain Health Services—part 4 of 6	34
Association between polygenic risk score of Alzheimer’s disease and plasma phosphorylated tau in individuals from the Alzheimer’s Disease Neuroimaging Initiative	34
Correlating natural language processing and automated speech analysis with clinician assessment to quantify speech-language changes in mild cognitive impairment and Alzheimer’s dementia	33
Enhancing magnetic resonance imaging-driven Alzheimer’s disease classification performance using generative adversarial learning	33
Prognosis prediction model for conversion from mild cognitive impairment to Alzheimer’s disease created by integrative analysis of multi-omics data	33
Herpesvirus infections and Alzheimer’s disease: a Mendelian randomization study	32
Diagnostic value of plasma p-tau181, NfL, and GFAP in a clinical setting cohort of prevalent neurodegenerative dementias	32
Impact of multisession 40Hz tACS on hippocampal perfusion in patients with Alzheimer’s disease	32
Predict Alzheimer’s disease using hippocampus MRI data: a lightweight 3D deep convolutional network model with visual and global shape representations	32
Associations between social and intellectual activities with cognitive trajectories in Chinese middle-aged and older adults: a nationally representative cohort study	32
Cerebrospinal fluid A beta 1–40 peptides increase in Alzheimer’s disease and are highly correlated with phospho-tau in control individuals	32
Cathepsin D regulates cerebral Aβ42/40 ratios via differential degradation of Aβ42 and Aβ40	32
Differential blood miRNA expression in brain amyloid imaging-defined Alzheimer’s disease and controls	32
Longitudinal amyloid and tau accumulation in autosomal dominant Alzheimer’s disease: findings from the Colombia-Boston (COLBOS) biomarker study	32
Glucose metabolism and AD: evidence for a potential diabetes type 3	32
Huanglian Jiedu decoction remodels the periphery microenvironment to inhibit Alzheimer’s disease progression based on the “brain-gut” axis through multiple integrated omics	32
RETRACTED ARTICLE: Preservation of dendritic spine morphology and postsynaptic signaling markers after treatment with solid lipid curcumin particles in the 5xFAD mouse model of Alzheimer’s amyloidosis	31
Does insulin resistance influence neurodegeneration in non-diabetic Alzheimer’s subjects?	31
The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer’s disease: a literature review	31
Severe COVID-19 in Alzheimer’s disease: APOE4’s fault again?	31
Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease	31
Physical exercise during exposure to 40-Hz light flicker improves cognitive functions in the 3xTg mouse model of Alzheimer’s disease	31
Plasma pTau181 predicts cortical brain atrophy in aging and Alzheimer’s disease	31
The short-term effects of sedentary behaviour on cerebral hemodynamics and cognitive performance in older adults: a cross-over design on the potential impact of mental and/or physical activity	31
Glucose metabolism in the right middle temporal gyrus could be a potential biomarker for subjective cognitive decline: a study of a Han population	31
TREM2 Alzheimer’s variant R47H causes similar transcriptional dysregulation to knockout, yet only subtle functional phenotypes in human iPSC-derived macrophages	31
Comparison of plasma neurofilament light and total tau as neurodegeneration markers: associations with cognitive and neuroimaging outcomes	30
Combination of snapshot hyperspectral retinal imaging and optical coherence tomography to identify Alzheimer’s disease patients	30
An MRI-based strategy for differentiation of frontotemporal dementia and Alzheimer’s disease	30
Challenges and opportunities for improving the landscape for Lewy body dementia clinical trials	29
Conditional genetic deletion of CSF1 receptor in microglia ameliorates the physiopathology of Alzheimer’s disease	29
Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer’s disease in individuals with subjective cognitive decline	28
Pilot study of repeated blood-brain barrier disruption in patients with mild Alzheimer’s disease with an implantable ultrasound device	28
Developing methods to detect and diagnose chronic traumatic encephalopathy during life: rationale, design, and methodology for the DIAGNOSE CTE Research Project	28
Detection of dementia on voice recordings using deep learning: a Framingham Heart Study	28
Normalization of CSF pTau measurement by Aβ40 improves its performance as a biomarker of Alzheimer’s disease	28
Artificial intelligence-based computational framework for drug-target prioritization and inference of novel repositionable drugs for Alzheimer’s disease	28
Perivascular spaces are associated with tau pathophysiology and synaptic dysfunction in early Alzheimer’s continuum	28
In vivo human molecular neuroimaging of dopaminergic vulnerability along the Alzheimer’s disease phases	27
The contribution of vascular risk factors in neurodegenerative disorders: from mild cognitive impairment to Alzheimer’s disease	27
The use of angiotensin-converting enzyme inhibitors vs. angiotensin receptor blockers and cognitive decline in Alzheimer’s disease: the importance of blood-brain barrier penetration and APOE ε4 carrie	27
APOE ε4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer’s disease	27
Characterization of the chromatin accessibility in an Alzheimer’s disease (AD) mouse model	27
MIND diet and the risk of dementia: a population-based study	27
Remote monitoring technologies in Alzheimer’s disease: design of the RADAR-AD study	27
Apolipoprotein E and sex modulate fatty acid metabolism in a prospective observational study of cognitive decline	26
Prognostic value of amyloid/tau/neurodegeneration (ATN) classification based on diagnostic cerebrospinal fluid samples for Alzheimer’s disease	26
Novel antibodies detect additional α-synuclein pathology in synucleinopathies: potential development for immunotherapy	26
Diverse proteins aggregate in mild cognitive impairment and Alzheimer’s disease brain	25
Prediction of differentially expressed microRNAs in blood as potential biomarkers for Alzheimer’s disease by meta-analysis and adaptive boosting ensemble learning	25
Longitudinal changes in EEG power, sleep cycles and behaviour in a tau model of neurodegeneration	25
Early detection of amyloid load using 18F-florbetaben PET	25
The efficacy of exergaming in people with major neurocognitive disorder residing in long-term care facilities: a pilot randomized controlled trial	25
White matter hyperintensities in autopsy-confirmed frontotemporal lobar degeneration and Alzheimer’s disease	24
The pleiotropic role of p53 in functional/dysfunctional neurons: focus on pathogenesis and diagnosis of Alzheimer’s disease	24
The two faces of synaptic failure in AppNL-G-F knock-in mice	24
Early diagnosis of Alzheimer’s disease using machine learning: a multi-diagnostic, generalizable approach	24
Characteristics and progression of patients with frontotemporal dementia in a regional memory clinic network	24
Genome-wide epistasis analysis for Alzheimer’s disease and implications for genetic risk prediction	24
Considerations regarding a diagnosis of Alzheimer’s disease before dementia: a systematic review	24
Association between retinal thickness and β-amyloid brain accumulation in individuals with subjective cognitive decline: Fundació ACE Healthy Brain Initiative	23
Topographic patterns of white matter hyperintensities are associated with multimodal neuroimaging biomarkers of Alzheimer’s disease	23
Efficacy and safety of pharmacotherapy for Alzheimer’s disease and for behavioural and psychological symptoms of dementia in older patients with moderate and severe functional impairments: a systemati	23
Baseline cognition is the best predictor of 4-year cognitive change in cognitively intact older adults	23
Young blood plasma reduces Alzheimer’s disease-like brain pathologies and ameliorates cognitive impairment in 3×Tg-AD mice	23
Distinct network topology in Alzheimer’s disease and behavioral variant frontotemporal dementia	23
FDG-PET hypermetabolism is associated with higher tau-PET in mild cognitive impairment at low amyloid-PET levels	23
A computerized version of the Short Form of the Face-Name Associative Memory Exam (FACEmemory®) for the early detection of Alzheimer’s disease	23
Trichostatin A ameliorates Alzheimer’s disease-related pathology and cognitive deficits by increasing albumin expression and Aβ clearance in APP/PS1 mice	23
Brain Health Services: organization, structure, and challenges for implementation. A user manual for Brain Health Services—part 1 of 6	23
Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease	23
Assessing what matters most to patients with or at risk for Alzheimer’s and care partners: a qualitative study evaluating symptoms, impacts, and outcomes	23
Diagnostic value of serum versus plasma phospho-tau for Alzheimer’s disease	23
Use of the Clock Drawing Test and the Rey–Osterrieth Complex Figure Test-copy with convolutional neural networks to predict cognitive impairment	22
Amyloid precursor protein glycosylation is altered in the brain of patients with Alzheimer’s disease	22

Verbal intelligence is a more robust cross-sectional measure of cognitive reserve than level of education in healthy older adults	22
Estimating the potential for dementia prevention through modifiable risk factors elimination in the real-world setting: a population-based study	22
Age and sex impact plasma NFL and t-Tau trajectories in individuals with subjective memory complaints: a 3-year follow-up study	22
Combination of gut microbiota and plasma amyloid-β as a potential index for identifying preclinical Alzheimer’s disease: a cross-sectional analysis from the SILCODE study	22
Classification accuracy of blood-based and neurophysiological markers in the differential diagnosis of Alzheimer’s disease and frontotemporal lobar degeneration	21
Subjective cognitive decline and subsequent dementia: a nationwide cohort study of 579,710 people aged 66 years in South Korea	21
Sex-specific associations with cerebrospinal fluid biomarkers in dementia with Lewy bodies	21
A multiscale brain network model links Alzheimer’s disease-mediated neuronal hyperactivity to large-scale oscillatory slowing	21
Longitudinal trajectories of Alzheimer’s ATN biomarkers in elderly persons without dementia	21
Partial reduction of amyloid β production by β-secretase inhibitors does not decrease synaptic transmission	21
Dementia risk communication. A user manual for Brain Health Services—part 3 of 6	20
Chemical genetic activation of the cholinergic basal forebrain hippocampal circuit rescues memory loss in Alzheimer’s disease	20
Short leukocyte telomeres predict 25-year Alzheimer's disease incidence in non-APOE ε4-carriers	20
Reversible GABAergic dysfunction involved in hippocampal hyperactivity predicts early-stage Alzheimer disease in a mouse model	20
In vivo staging of frontotemporal lobar degeneration TDP-43 type C pathology	20
Visual short-term memory relates to tau and amyloid burdens in preclinical autosomal dominant Alzheimer’s disease	20
The role of interleukin-33 in patients with mild cognitive impairment and Alzheimer’s disease	20
Dynamics of plasma biomarkers in Down syndrome: the relative levels of Aβ42 decrease with age, whereas NT1 tau and NfL increase	20
Altered central and blood glutathione in Alzheimer’s disease and mild cognitive impairment: a meta-analysis	20
Race, APOE genotypes, and cognitive decline among middle-aged urban adults	19
Prediction of Alzheimer’s disease biomarker status defined by the ‘ATN framework’ among cognitively healthy individuals: results from the EPAD longitudinal cohort study	19
Plasma transferrin and hemopexin are associated with altered Aβ uptake and cognitive decline in Alzheimer’s disease pathology	19
Association of plasma and CSF cytochrome P450, soluble epoxide hydrolase, and ethanolamide metabolism with Alzheimer’s disease	19
Association between physical activity and conversion from mild cognitive impairment to dementia	19
Trajectories of subjective cognitive decline, and the risk of mild cognitive impairment and dementia	19
CSF levels of the BACE1 substrate NRG1 correlate with cognition in Alzheimer’s disease	19
Near-infrared light reduces β-amyloid-stimulated microglial toxicity and enhances survival of neurons: mechanisms of light therapy for Alzheimer’s disease	19
The dynamics of plasma biomarkers across the Alzheimer’s continuum	19
Associations between vascular risk factors and subsequent Alzheimer’s disease in older adults	19
Kidney function and dementia risk in community-dwelling older adults: the Shanghai Aging Study	19
Characterization of symptoms and determinants of disease burden in dementia with Lewy bodies: DEvELOP design and baseline results	19
Structural MRI profiles and tau correlates of atrophy in autopsy-confirmed CTE	19
Associations between locus coeruleus integrity and nocturnal awakenings in the context of Alzheimer’s disease plasma biomarkers: a 7T MRI study	19
Improving 3D convolutional neural network comprehensibility via interactive visualization of relevance maps: evaluation in Alzheimer’s disease	19
Data analysis with Shapley values for automatic subject selection in Alzheimer’s disease data sets using interpretable machine learning	18
Serum neurofilament light chain level as a predictor of cognitive stage transition	18
Diagnostic and prognostic value of plasma neurofilament light and total-tau in sporadic Creutzfeldt-Jakob disease	18
Energy intake and expenditure in patients with Alzheimer’s disease and mild cognitive impairment: the NUDAD project	18
COVID-19 in adults with dementia: clinical features and risk factors of mortality—a clinical cohort study on 125 patients	18
Diagnostic and prognostic performance to detect Alzheimer’s disease and clinical progression of a novel assay for plasma p-tau217	18
An analysis of genetically regulated gene expression across multiple tissues implicates novel gene candidates in Alzheimer’s disease	18
Role of liraglutide in Alzheimer’s disease pathology	18
27-Hydroxycholesterol, cognition, and brain imaging markers in the FINGER randomized controlled trial	18
Methotrexate and relative risk of dementia amongst patients with rheumatoid arthritis: a multi-national multi-database case-control study	18
Comorbidity between Alzheimer’s disease and major depression: a behavioural and transcriptomic characterization study in mice	17
Perspectives and challenges in patient stratification in Alzheimer’s disease	17
Plasma Aβ and neurofilament light chain are associated with cognitive and physical function decline in non-dementia older adults	17
Mendelian randomization highlights significant difference and genetic heterogeneity in clinically diagnosed Alzheimer’s disease GWAS and self-report proxy phenotype GWAX	17
Neuropsychiatric symptoms in at-risk groups for AD dementia and their association with worry and AD biomarkers—results from the DELCODE study	17
Association of glial and neuronal degeneration markers with Alzheimer’s disease cerebrospinal fluid profile and cognitive functions	17
Awareness of cognitive decline trajectories in asymptomatic individuals at risk for AD	17
Amyloid-β1–43 cerebrospinal fluid levels and the interpretation of APP, PSEN1 and PSEN2 mutations	17
Immunomodulatory sphingosine-1-phosphates as plasma biomarkers of Alzheimer’s disease and vascular cognitive impairment	17
Aquaporin-4 cerebrospinal fluid levels are higher in neurodegenerative dementia: looking at glymphatic system dysregulation	17
Measuring cortical mean diffusivity to assess early microstructural cortical change in presymptomatic familial Alzheimer’s disease	17
Increased levels of the synaptic proteins PSD-95, SNAP-25, and neurogranin in the cerebrospinal fluid of patients with Alzheimer’s disease	17
Genetically determined blood pressure, antihypertensive medications, and risk of Alzheimer’s disease: a Mendelian randomization study	17
The Aβ1–42/Aβ1–40 ratio in CSF is more strongly associated to tau markers and clinical progression than Aβ1–42 alone	17
The Alzheimer’s Prevention Initiative Composite Cognitive Test: a practical measure for tracking cognitive decline in preclinical Alzheimer’s disease	17
Plasma amyloid-β oligomerization assay as a pre-screening test for amyloid status	16
Differential effects of risk factors on the cognitive trajectory of early- and late-onset Alzheimer’s disease	16
Four subgroups based on tau levels in Alzheimer’s disease observed in two independent cohorts	16
The cerebrospinal fluid biomarker ratio Aβ42/40 identifies amyloid positron emission tomography positivity better than Aβ42 alone in a heterogeneous memory clinic cohort	16
A novel age-informed approach for genetic association analysis in Alzheimer’s disease	16
Cholinergic receptor binding in unimpaired older adults, mild cognitive impairment, and Alzheimer’s disease dementia	16
Neurodegenerative changes in early- and late-onset cognitive impairment with and without brain amyloidosis	16
Differential diagnostic value of total alpha-synuclein assay in the cerebrospinal fluid between Alzheimer’s disease and dementia with Lewy bodies from the prodromal stage	16
Behavioral, neuromorphological, and neurobiochemical effects induced by omega-3 fatty acids following basal forebrain cholinergic depletion in aged mice	16
Performance of a fully-automated Lumipulse plasma phospho-tau181 assay for Alzheimer’s disease	16
Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer’s dementia in mild cognitive impairment patients	16
Blood and brain transcriptome analysis reveals APOE genotype-mediated and immune-related pathways involved in Alzheimer disease	16
A deep learning MRI approach outperforms other biomarkers of prodromal Alzheimer’s disease	16
Accelerated long-term forgetting in healthy older adults predicts cognitive decline over 1 year	15
Gut–microbiota–microglia–brain interactions in Alzheimer’s disease: knowledge-based, multi-dimensional characterization	15
Long-term low-dose acetylsalicylic use shows protective potential for the development of both vascular dementia and Alzheimer’s disease in patients with coronary heart disease but not in other individ	15
Beneficial association of angiotensin-converting enzyme inhibitors and statins on the occurrence of possible Alzheimer’s disease after traumatic brain injury	15
Efficacy and safety of GV1001 in patients with moderate-to-severe Alzheimer’s disease already receiving donepezil: a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial	15
High-intensity exercise and cognitive function in cognitively normal older adults: a pilot randomised clinical trial	15
Eicosanoid lipidome activation in post-mortem brain tissues of individuals with APOE4 and Alzheimer’s dementia	15
Protocols for cognitive enhancement. A user manual for Brain Health Services—part 5 of 6	15
Recurrent and concurrent patterns of regional BOLD dynamics and functional connectivity dynamics in cognitive decline	15
Multi-trait association studies discover pleiotropic loci between Alzheimer’s disease and cardiometabolic traits	15
β-Secretase1 biological markers for Alzheimer’s disease: state-of-art of validation and qualification	15
The relationship between physical activity, apolipoprotein E ε4 carriage, and brain health	15
Association of peripheral immunity with cognition, neuroimaging, and Alzheimer’s pathology	15
CERTL reduces C16 ceramide, amyloid-β levels, and inflammation in a model of Alzheimer’s disease	14
Prodromal characteristics of dementia with Lewy bodies: baseline results of the MEMENTO memory clinics nationwide cohort	14
Repurposing beta-3 adrenergic receptor agonists for Alzheimer’s disease: beneficial effects in a mouse model	14
The circadian rest-activity pattern predicts cognitive decline among mild-moderate Alzheimer’s disease patients	14
Age, vascular disease, and Alzheimer’s disease pathologies in amyloid negative elderly adults	14
Rationale and study design of a randomized, placebo-controlled, double-blind phase 2b trial to evaluate efficacy, safety, and tolerability of an oral glutaminyl cyclase inhibitor varoglutamstat (PQ912	14
Investigating the clinico-anatomical dissociation in the behavioral variant of Alzheimer disease	14
Brain connectivity and metacognition in persons with subjective cognitive decline (COSCODE): rationale and study design	14
Disparities in the participation and adherence of older adults in lifestyle-based multidomain dementia prevention and the motivational role of perceived disease risk and intervention benefits: an obse	14
Serum zinc levels and in vivo beta-amyloid deposition in the human brain	14